CMS Open Payments · Program Year 2024
J. Morita USA, Inc.
J. Morita USA, Inc. reported $263,163.22 across General Payments, Research, and Ownership to 94 physicians and teaching hospitals across 99 transactions.
- $263.2K Above-median payer
- All-tracks total
- 99 Below-median volume
- Transactions
- 94 Below-median reach
- Recipients
- −$78.0K
- General Payments vs PY2023
J. Morita USA, Inc. reported $263,163.22 across all CMS Open Payments tracks (General + Research + Ownership) to 94 physicians and teaching hospitals in Program Year 2024 - ranking #920 of 1,925 reporting manufacturers (0.0% of the all-tracks industry total); General Payments alone were $88,165.72, averaging $2.8K per recipient.
How J. Morita USA, Inc.'s $263.2K all-tracks total breaks down
J. Morita USA, Inc.'s payment reach score
Each tracked dimension is percentile-scored against the national companies corpus, then averaged across only the dimensions that apply to this company, a neutral scale measure of reporting activity, not a rating of quality, safety, or ethics.
Overall reach score
F
28/100
Total payments
F
12/100
Transaction volume
F
11/100
Physician reach
F
11/100
Payment type diversity
C
77/100
Data currency: Figures are rendered from the processed CMS Open Payments release. See our methodology for source dates and refresh cadence. Spot a figure that looks wrong? Report a correction.
CMS Sunshine Act warrant
Manufacturer j-morita-usa-inc J. Morita USA, Inc.
$263.2K · #920/1,925 · 0.0% industry · PY2024
- TOT $263.2K
- RANK #920
- SHARE 0.0%
- TXN 99
- RCP 94
- CAT 6
- GEN $88.2K
- ΔGEN −$78.0K
- TOP1 56.7%
- PY 2024
Volume peers
Nearest volume peer: THD America, Inc. ($263.2K)
J. Morita USA, Inc. sits among 1,925 manufacturers disclosing under the Physician Payments Sunshine Act. Volume peers below are nearest by all-tracks total, not corporate affiliates. Open the company rankings →
Release-over-release change
General Payments changed from PY2023 to PY2024
J. Morita USA, Inc.'s CMS-reported General Payments decreased by $78.0K (−46.9%) from PY2023 to PY2024.
How this year-over-year comparison is scoped
The comparison uses consecutive CMS program years only (current = prior + 1) from the manufacturer General Payments summary and excludes research and ownership or investment records. Non-consecutive year pairs are not shown as year-over-year change. This General Payments figure is not the all-tracks company total in the hero.
CMS source labels for this exact identifier: PY2022: J. MORITA USA, INC.PY2023: J. MORITA USA, INC.PY2024: J. Morita USA, Inc.. Matching identifiers support a bounded record comparison; a label difference would be reported as unresolved rather than treated as a corporate event.
Subscribe to this company's source-bounded update feed It publishes only identifier-matched CMS release comparisons, never inferred company events.
General Payments: PY2023 vs PY2024
Annual CMS-reported totals for this company, not an all-category Open Payments total
- PY2023
- $166,192.38
- PY2024
- $88,165.72
What the Data Shows for J. Morita USA, Inc.
The all-tracks total above combines three CMS reporting categories - General Payments, Research Payments, and Ownership/Investment interests - not one undifferentiated figure. For J. Morita USA, Inc., that total blends General Payments (day-to-day consulting, meals, travel and speaking fees, shown separately above) with Research and Ownership/Investment interest records, each governed by its own CMS reporting rules. CMS publishes each Program Year's data roughly 12 months after the reporting period ends, so this reflects the most recently released cycle; see our methodology for how the tracks are standardized and compared across companies.
The 6-category breakdown below covers general payments only (see our methodology for how research and ownership payments are reported separately). The largest general-payment category is "Consulting Fee" at $34.5K, accounting for 39.1% of this company's General Payments and 12 transactions.
General Payment Breakdown by Type
"Consulting Fee" leads J. Morita USA, Inc.'s 6-category general-payment breakdown at $34.5K, 39.1% of the reported total.
J. Morita USA, Inc. reports 6 general-payment categories - the top three are Consulting Fee (39.1%), Compensation for Services Other Than Consulting (37.4%), and Education (11.8%). The remaining 3 categories make up 11.6% of this company's reported general-payment total. That multi-category mix is the kind of profile single-category reporters cannot show.
How J. Morita USA, Inc. divides its payments
Top payment categories by total reported dollar volume
| Payment Type | Amount | Transactions | % of Total |
|---|---|---|---|
| Consulting Fee | $34.5K | 12 | 39.1% |
| Compensation for Services Other Than Consulting | $33.0K | 12 | 37.4% |
| Education | $10.4K | 9 | 11.8% |
| Travel and Lodging | $9.1K | 10 | 10.3% |
| Food and Beverage | $1.1K | 46 | 1.3% |
| Gift | $50.00 | 5 | 0.1% |
Recipient Concentration in General Payments
The five largest recipient relationships account for $76,795.21 (87.1%) of $88,165.72 in this company's General Payments records across 52 recipients.
General Payments scope note
Program Year 2024 General Payments view only: excludes research and ownership/investment records, so it is not the all-category company total above.
Largest General-Payment relationships for J. Morita USA, Inc.
The five named recipients with the highest reported General Payments from this company
- 1
Bruno Azevedo
$49,981.85 across 25 reported transactions
- 2
Douglas Gairns Ness
$8,759.57 across 3 reported transactions
- 3
Donald S Clem
$7,614.80 across 2 reported transactions
- 4
Aaron Andrew Nicholas
$6,000.00 across 6 reported transactions
- 5
Board of Trustees of the University
$4,438.99 across 3 reported transactions
Compare this company's payment profile with similarly sized manufacturers in the company comparison tool, and consult the methodology for the CMS source scope.
Spend vs. Concentration
J. Morita USA, Inc. ranks #920 of 1,925 by total payments (top 48% by spend) but is notably more concentrated than that alone would suggest -- #502 of 1,838 by HHI (top 27% most concentrated). Its payments land on an unusually narrow set of recipients for its spend size.
View all 12 companies in this HHI neighborhood as a list
- CMF Medicon Surgical Inc. : $9.8K total payments, HHI 3560
- Fresenius Kabi USA, LLC : $1.3M total payments, HHI 3555
- Immunocore Limited : $1.1M total payments, HHI 3543
- GastroGPO, LLC : $3.7K total payments, HHI 3528
- Pfizer Chile S.a. : $16.9K total payments, HHI 3528
- Verathon Inc. : $672.8K total payments, HHI 3520
- J. Morita USA, Inc. (this company) : $88.2K total payments, HHI 3500
- DTE Oregon, Inc. : $304.57 total payments, HHI 3497
- Alcon Research LLC : $7.1M total payments, HHI 3482
- Winter Innovations, Inc. : $4.7K total payments, HHI 3468
- ONY Biotech Inc. : $39.6K total payments, HHI 3464
- Cardinal Health 110 LLC : $92.3K total payments, HHI 3463
Similarly Concentrated Companies
Companies whose General Payments are spread across recipients about as (un)evenly as J. Morita USA, Inc.'s, measured by the same HHI concentration index above, not by payment size.
What HHI 2,500 means here
2,500 is the DOJ/FTC merger-guidelines threshold for "highly concentrated" markets; used here only as a familiar concentration reference, not a legal finding about J. Morita USA, Inc..
Companies with Similar Payment Volumes
Open a profile or compare a similar company's CMS-reported payment pattern with J. Morita USA, Inc..
Showing 6 of 1,924 companies with CMS-reported payment data.
Evolution Spine, LLC
Endomagnetics Ltd
IBSA Pharma Inc.
Sterilmed, Inc.
Creo Medical Inc.
Put this to use
J. Morita USA, Inc. ranks #920 of 1,925 by all-tracks total payments, led by "Consulting Fee".
- See how manufacturer spending compares across the full leaderboard. Top 100 by total payments
- Compare "Consulting Fee" spend across every manufacturer, not just J. Morita USA, Inc.. Payment type breakdowns
- New to Open Payments? Learn what these figures do and do not show. Read the guide
Reported payments reflect what companies disclosed to CMS; a payment is not evidence of wrongdoing.
Disclaimer
This information is provided for informational purposes only and does not constitute professional advice. Data is sourced from the CMS Open Payments program. Consult a qualified professional before making decisions based on this data.
Read our methodology - how this data is sourced, computed, and verified.
Every figure on PlainPharmaWatch is rendered directly from federal source data, no number is typed in by an editor. This page draws directly on federal source data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error. Data current as of 2026-07-26.